Evidence Strength Explorer
Every compound in the library classified by its highest available clinical evidence tier — from FDA-approved indications to preclinical animal data. Filter by level to compare the research maturity of different compounds side by side.
Research reference only. Evidence tiers reflect the highest level of published data for each compound as of the last database update. Higher evidence does not imply safety or suitability for any specific research use. Full disclaimer.
FDA-approved (Ozempic, Wegovy, Rybelsus)
Extensive Phase III RCT data (SUSTAIN, STEP trials)
FDA-approved (Mounjaro, Zepbound)
Phase III SURPASS trial program
FDA-approved (Victoza, Saxenda)
LEADER cardiovascular outcomes trial
FDA-approved (Egrifta) for HIV lipodystrophy
Two Phase III RCTs in HIV patients
FDA-approved (Vyleesi) for HSDD
Phase III RECONNECT trials
FDA-approved as Bremelanotide (Vyleesi)
Phase III RECONNECT trials
FDA-approved for fertility indications
Extensive clinical use data
FDA-approved as Menopur/Repronex
Extensive ART clinical trial data
FDA-approved (Somatropin) for GH deficiency
Multiple approved indications with Phase III data
FDA-approved historically; widely compounded
Clinical PK data and GH deficiency studies
FDA-approved (Factrel) for hypothalamic amenorrhea
Used clinically for pulsatile GnRH therapy
FDA-approved (Pitocin) for obstetric indications
Extensive obstetric and research literature
FDA-approved injectable cyanocobalamin
Well-established clinical pharmacology
FDA-approved (Carnitor) for carnitine deficiency
Multiple RCTs in carnitine deficiency and dialysis
EMA-approved (Scenesse) for erythropoietic protoporphyria
Phase III CLINUVEL trials
Approved in China, Philippines and other markets (Zadaxin)
Phase III hepatitis B and C trials
Approved in Japan (Adlumiz) for cancer cachexia
ROMANA Phase III trial program
Approved in Europe and Asia for stroke/neurodegeneration
Multiple Phase III RCTs; Cochrane reviews available
Phase III TRIUMPH program ongoing (2024–2026)
Phase II/III completed for Duchenne and BMD; program halted due to AEs
Phase III MK-677 trials in GH deficiency and hip fracture
Phase III TE-RANO-1 obesity trial completed
Small Phase I/II pilot trials; IBD and joint pain endpoints
Registered Phase II trials in Russia (stroke, cognitive function)
Russian registry Phase II trials (anxiety, cognitive)
Russian Phase II trials; anti-aging and oncology contexts
Phase II Increlex (mecasermin) data; LR3 variant separate
Multiple Phase II trials (MMPOWER-3, EMBRACE) for Barth syndrome and HFpEF
Phase II trials for PAH, COPD, and septic shock
Phase II fertility trials (LH pulsatility, IVF trigger)
Multiple Phase II trials (NMN/NAD+ precursors in aging, metabolic disease)
Phase II investigational data in metabolic syndrome
Early Phase II data in insulin resistance and exercise capacity
Phase II gene therapy trials (rAAV1-FS344) in Becker muscular dystrophy
Historical Phase II trials (1980s–1990s) in sleep disorders
Phase I PK/safety data available
Phase I PK studies and small clinical studies
Phase I safety studies; cardiologic Phase I data
Phase I cardiovascular safety data; no further development
Phase I safety confirmed; Phase IIb adiposity trials terminated
Phase I/II data in sarcoidosis neuropathy
Phase I safety data in wound healing and periodontitis
Phase I/II oral formulation for Crohn's disease (ongoing)
Phase I safety data; no further regulated development
Phase I/II CHAMP trial (cardiac repair) completed 2022
Phase I PK/GH secretion studies; further development stalled
Phase I topical wound healing trials; limited systemic data
Preclinical only; no registered human trials as of 2026
Preclinical cognitive research; no human data
Preclinical neuroprotection studies
Preclinical NNMT inhibition studies; no human PK data
Preclinical anabolic studies; no registered human trials
IV glutathione limited human data; antioxidant research context
Preclinical immune studies; limited human registry data